3篇
您的检索式：作者名="MILTON;Luke"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A modification of the luke multiresidue procedure for low moisture,nonfatty products显示文摘 | Milton A Luke Doose G M | 1983 | Bulletin of Environmental Contamination and Toxicology1983，30，1： | 1 |
| 2 | Poly(thiourea triethylene glycol) as a multifunctional binder for enhanced performance in lithium-sulfur batteries显示文摘A mechanically strong binder with polar functional groups could overcome the dilemma of the large volume change during charge/discharge processes and poor cyclability of lithium-sulfur batteries(LSBs).In this work,for the first time,we report the use of poly(thiourea triethylene glycol)(PTTG)as a multifunctional binder for sulfur cathodes to enhance the performance of LSBs.As expected,the PTTG binder facilitates the high performance and stability delivered by the Sulfur-PTTG cathode,including a higher reversible capacity of 825 mAh g^(-1) at 0.2 C after 80 cycles,a lower capacity fading(0.123%per cycle)over 350 cycles at 0.5 C,a higher areal capacity of 2.5 mAh cm^(-2) at 0.25 mA cm^(-2),and better rate capability of 587 mAh g^(-1) at 2 C.Such superior electrochemical performances could be attributed to PTTG's strong chemical adsorption towards polysulfides which may avoid the lithium polysulfide shuttle effect and excellent mechanical characteristics which prevents electrode collapse during cycling and allows the Sulfur-PTTG electrode to maintain robust electron and ion migration pathways for accelerated redox reaction kinetics. | Luke Hencz Hao Chen Zhenzhen Wu Xingxing Gu Meng Li Yuhui Tian Su Chen Cheng Yan Abdulaziz S.R.Bati Joseph G.Shapter Milton Kiefel Dong-Sheng Li Shanqing Zhang | 2022 | Green Energy & Environment2022，7，6： | 0 |
| 3 | 美国临床肿瘤学会IV期非小细胞肺癌化疗的临床实践指南更新显示文摘本文旨在为IV期非小细胞肺癌患者的治疗提供更新版推荐。本文资料检索源自2002年以来公布的相关随机试验文献。此指南范围限于化疗与生物治疗。更新委员会对这些文献进行了总结并提供了推荐更新。162篇文献符合标准被纳入参考。本推荐基于可改善总生存期的治疗方法。仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测。对于体力状态评分为0分或1分患者的一线治疗,可推荐以铂类为基础的细胞毒性药物的两药联用。对铂类治疗有禁忌的患者,可采用非铂类细胞毒性两药联合。对于体力状态评分为2分的患者,单一细胞毒性药物即可。对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者,应停止一线细胞毒性化疗。即使在6个周期后患者对治疗仍有反应,亦应停止两药细胞毒性化疗。对于伴有明确的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的患者,可推荐一线采用吉非替尼治疗;对于EGFR突变为阴性或不明确的患者,细胞毒性化疗更佳。除具有特定临床特征的患者外,可推荐贝伐单抗与卡铂-紫杉醇联用。对于通过免疫组化证实EGFR阳性的肿瘤患者,可推荐西妥昔单抗与顺铂-长春瑞滨联用。多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗。对于未曾接受过厄洛替尼或吉非替尼治疗的患者,可推荐厄洛替尼作为三线治疗。现有数据不足以推荐常规三线采用细胞毒性药物。已有的证据也不足以推荐常规应用分子标记物选择化疗。 | Christopher G. AZZOLI Sherman Baker JR Sarah TEMIN William PAO Timothy ALIFF Julie BRAHMER David H. JOHNSON Janessa L. LASKIN Gregory MASTERS Daniel MILTON Luke NORDQUIST David G. PFISTER Steven PIANTADOSI Joan H. SCHILLER Reily SMITH Thomas J. SMITH John R. STRAWN David TRENT Giuseppe GIACCONE 丁燕(翻译) 南娟(翻译) 刘谦(翻译) 周清华(校对) 陈军(校对) | 2010 | 中国肺癌杂志2010，13，3： | 43 |
您所在的机构暂未开通此部分的功能，请联系管理员